GAPDH Antibody (6C5cc)

Simple Western: GAPDH Antibody (6C5cc) [NB600-502]

Simple Western: GAPDH Antibody (6C5) [NB600-502] - Simple Western lane view shows a specific band for GAPDH in 0.5 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system. Note: band observed higher than predicted 36 kDa molecular weight.

Simple Western: GAPDH Antibody (6C5cc) [NB600-502]

Simple Western: GAPDH Antibody (6C5) [NB600-502] - Anaylsis in rat brain and spinal cord. This image includes the GAPDH at the predicted kDa as well as a glucocorticoid receptor antibody (peak 102). Verified customer review.

Western Blot: GAPDH Antibody (6C5cc) [NB600-502] -

Western Blot: GAPDH Antibody (6C5cc) [NB600-502] - Western blot analysis for whole cell & nuclear signal transduction proteins. (A) Phosphorylated FAK (Y397) was significantly decreased at 24 h & significantly increased at 48 h as compared to sham. (B) Nuclear localization of corresponding signal transduction molecules, p38, & p65, were decreased at 24 h & increased at 48 h as compared to sham. *p < 0.05, #p = 0.056, Data are represented as mean ± SEM, whole cell: n = 9–10/group; nuclear: n = 7–9/group. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30853931), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: GAPDH Antibody (6C5cc) [NB600-502] -

Western Blot: GAPDH Antibody (6C5cc) [NB600-502] - Upregulation of innate immune response genes in BRCA2-deficient human cells. a Venn diagram of common genes upregulated in H1299 & MDA-MB-231 human cells, upon chronic (28 days) DOX-induced BRCA2 depletion. b Gene set enrichment analysis (Gene Ontology—Biological Process database) of the 28 genes upregulated upon chronic BRCA2 inactivation in both H1299 & MDA-MB-231 cells. c, d Whole-cell extracts prepared after 4 & 28 days of DOX treatment were immunoblotted as indicated. GAPDH was used as a loading control. Phosphorylation site are indicated in red Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31316060), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: GAPDH Antibody (6C5cc) [NB600-502] -

Western Blot: GAPDH Antibody (6C5cc) [NB600-502] - FGF23 expression in the partial nephrectomy rat model.(a) Serum FGF23 concentration. (b) FGF23 mRNA expression in the kidney. Sham group was used as a normalization control. (c) Western blot of FGF23 in the kidney. (d) Histology in the kidney. HE: hematoxylin-eosin staining. MT: Masson’s trichrome staining to evaluate fibrosis. VK: Von Kossa staining to evaluate calcification. *P<0.05, **P<0.01, ***P<0.001; sham group (n = 6), partial nephrectomy mild group (PN mild) (n = 6), partial nephrectomy severe group (PN severe) (n = 6). Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29518087), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: GAPDH Antibody (6C5cc) [NB600-502] -

Western Blot: GAPDH Antibody (6C5cc) [NB600-502] - FGF23 expression in hemi-nephrectomized rats fed a high-P diet.(a) Serum FGF23 concentration. (b) FGF23 mRNA expression in the bone. NP sham group was used as a normalization control. (c) FGF23 mRNA expression in the kidney. NP sham group was used as a normalization control. (d) Western blot of FGF23 in the kidney. GAPDH was used as an internal control. Each value shown represents the mean ± SEM; *P<0.05, **P<0.01; NP sham group (n = 8), NP Nx group (n = 7), HP sham group (n = 7) & HP Nx group (n = 9). Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29518087), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: GAPDH Antibody (6C5cc) [NB600-502] -

Western Blot: GAPDH Antibody (6C5cc) [NB600-502] - Time course of innate immune response activation in BRCA2-deficient cells. a H1299 cells expressing a DOX-inducible BRCA2 shRNA were grown in the presence or absence of DOX for 28 days. Cells collected every 2 days were subjected to quantitative RT-PCR analyses using primers specific for indicated genes. mRNA levels were expressed relative to the gene encoding beta-actin & to day 2 (2− delta deltaCT). n = 3 independent experiments, each performed in triplicates. Each dot represents a single replicate. b Whole-cell extracts prepared at indicated times after DOX addition were immunoblotted as shown. GAPDH was used as a loading control. Phosphorylation sites are indicated in red Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31316060), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: GAPDH Antibody (6C5cc) [NB600-502] -

Western Blot: GAPDH Antibody (6C5cc) [NB600-502] - Decreased proliferation rates in ALDH2‐deficient human fibroblasts upon HR abrogationA–CHuman fibroblasts carrying either WT ALDH2 or the E487K homozygous ALDH2 mutation were transfected with control (SCR) or siRNAs against BRCA1 (A), BRCA2 (B), or RAD51 (C). Cells were processed for proliferation assays 48 h after transfection. siRNAs were retransfected at an interval of 4 days. Graphs are representative of three independent experiments, each performed with three technical replicas. Error bars represent SD of three technical replica values obtained from a single experiment. Cell extracts were prepared 48 h after transfection & immunoblotted as shown. SMC1 or GAPDH were used as loading controls. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/28729482), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: GAPDH Antibody (6C5cc) [NB600-502] -

Western Blot: GAPDH Antibody (6C5cc) [NB600-502] - Upregulation of innate immune response genes in BRCA2-deficient human cells. a Venn diagram of common genes upregulated in H1299 & MDA-MB-231 human cells, upon chronic (28 days) DOX-induced BRCA2 depletion. b Gene set enrichment analysis (Gene Ontology—Biological Process database) of the 28 genes upregulated upon chronic BRCA2 inactivation in both H1299 & MDA-MB-231 cells. c, d Whole-cell extracts prepared after 4 & 28 days of DOX treatment were immunoblotted as indicated. GAPDH was used as a loading control. Phosphorylation site are indicated in red Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31316060), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: GAPDH Antibody (6C5cc) [NB600-502] -

Western Blot: GAPDH Antibody (6C5cc) [NB600-502] - CtIP is not required for degradation of the single-stranded telomeric overhang generated by TRF2 inactivationImmortalized MEFs were infected with retroviruses expressing the indicated shRNAs, followed by selection with puromycin for 72 h. Cell extracts were prepared 48 h later & analysed by Western blotting as indicated. SMC1 & GAPDH were used as loading controls. *non-specific band.MboI- & AluI-digested DNA from cells treated as in (A) was resolved by pulsed-field gel electrophoresis & probed with end-labelled (AACCCT)4 probe. Representative pulsed-field gel samples run under native & denatured conditions are shown.Quantification of the 3′ overhang in cells treated as in (B). For each sample, the ss/total DNA ratios were expressed relative to the GFP shRNA-treated control. Error bars represent SD of two independent experiments. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/25582120), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: GAPDH Antibody (6C5cc) [NB600-502] -

Western Blot: GAPDH Antibody (6C5cc) [NB600-502] - ISG induction in HR-deficient human cells & tumors & olaparib impact on this process. a Upregulation of innate immune response genes in BRCA2-deleted ovarian tumors (n = 4) versus tumors with median BRCA2 mRNA expression (n = 145). b Upregulation of innate immune response genes in RAD51-deleted ovarian tumors (n = 11) versus tumors with median RAD51 mRNA expression (n = 145). Dots in graphs represent individual tumors. Middle line (white), median; box limits 25 & 75 percentiles; whiskers, minimum & maximum values. c H1299 cells expressing a DOX-inducible BRCA2 shRNA were grown in the presence or absence of DOX for 4 days. Then, olaparib (1 or 10 µM) was added for 72 h, followed by quantitative RT-PCR analyses. Primers specific for the indicated genes were used. mRNA levels were expressed relative to the gene encoding beta-actin & to untreated (−DOX) control cells (2− delta deltaCT). Error bars represent SD of n = 3 independent experiments. *, p < 0.05 (unpaired two-tailed t test). d Whole-cell extracts from cells treated as in (c) were immunoblotted as shown. GAPDH & SMC1 were used as loading controls. Phosphorylation sites are indicated in red. e Cells treated as in (c) were pulse-labeled with EdU for 30 min. Frequency of cells in G1, S, & G2/M stages of the cell cycle were determined using FACS analyses of EdU incorporation & propidium iodide staining. Error bars represent SD of n = 3 independent experiments Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31316060), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: GAPDH Antibody (6C5cc) [NB600-502] -

Western Blot: GAPDH Antibody (6C5cc) [NB600-502] - BRCA1 & CtIP mediate Ku- & LIG4-independent telomere fusionsImmortalized Brca1F/− MEFs were infected with retroviruses expressing the indicated shRNAs and/or Cre recombinase, followed by selection with puromycin for 72 h. Mitotic chromosomes isolated 48 h later were fixed & stained with a Cy3-conjugated (CCCTAA)3-PNA probe. The frequency of end-to-end chromosome-type fusions is represented as a percentage of fusions observed after TRF2 depletion. A minimum of 2,000 chromosomes were scored for each sample. Error bars represent SD of three independent experiments. P-values were calculated using an unpaired two-tailed t-test. NS, P > 0.05.Immortalized Brca1F/C61G MEFs were infected with retroviruses expressing the indicated shRNAs and/or Cre recombinase, followed by selection with puromycin for 72 h. The frequency of end-to-end chromosome-type fusions was analysed as in (A).MEFs of the indicated genotypes were infected with retroviruses expressing TRF2 and/or CtIP shRNAs, followed by selection with puromycin for 72 h. Cell extracts were prepared 48 h later & analysed by Western blotting as indicated. GAPDH was used as a loading control. *non-specific band. Cells treated as in (C) & (E) were arrested in mitosis with colcemid, & mitotic chromosomes isolated 48 h later were fixed & stained with a Cy3-conjugated (CCCTAA)3-PNA probe (D, F). The frequency of end-to-end chromosome-type fusions is represented as a percentage of fusions observed after TRF2 depletion. Error bars represent SD of two independent experiments. P-values were calculated using an unpaired two-tailed t-test. *P ≤ 0.05. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/25582120), licensed under a CC-BY license. Not internally tested by Novus Biologicals.